Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International Study

被引:5
|
作者
Zaakouk, Mohamed [1 ,2 ]
Van Bockstal, Mieke [3 ,4 ]
Galant, Christine [3 ,4 ]
Callagy, Grace [5 ]
Provenzano, Elena [6 ,7 ,8 ]
Hunt, Roger [9 ]
D'Arrigo, Corrado [10 ]
Badr, Nahla M. [1 ,11 ]
O'Sullivan, Brendan [12 ]
Starczynski, Jane [13 ]
Tanchel, Bruce [13 ]
Mir, Yasmeen [14 ]
Lewis, Paul [15 ]
Shaaban, Abeer M. [1 ,12 ]
机构
[1] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, England
[2] Cairo Univ, Canc Pathol, Natl Canc Inst, Cairo 12613, Egypt
[3] Clin Univ St Luc Bruxelles, Dept Pathol, B-1200 Brussels, Belgium
[4] Catholic Univ Louvain, Inst Rech Experimentale & Clin, B-1348 Brussels, Belgium
[5] Univ Galway, Lambe Inst Translat Res, Sch Med, Discipline Pathol, Galway H91 TK33, Ireland
[6] NIHR Cambridge Biomed Res Ctr, Cambridge CB2 0QQ, England
[7] Addenbrookes Hosp, Cambridge CB2 0QQ, England
[8] Cambridge Univ NHS Fdn Trust, Dept Histopathol, Cambridge CB2 0QQ, England
[9] Wythenshawe Hosp, Dept Histopathol, Manchester M23 9LT, England
[10] Poundbury Canc Inst, Dorchester DT1 3BJ, England
[11] Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm 32952, Egypt
[12] Queen Elizabeth Hosp Birmingham, Cellular Pathol, Birmingham B15 2GW, England
[13] Heart England NHS Fdn Trust, Cellular Pathol, Birmingham B9 5ST, England
[14] Royal Liverpool & Broadgreen Univ Hosp, Pathol, Liverpool L7 8YE, England
[15] Swansea Univ, Med Sch, Singleton Pk, Swansea SA2 8PP, Wales
关键词
PD-L1; breast cancer; VENTANA SP142; triple-negative; LIGAND; 1; IMMUNOHISTOCHEMISTRY; CONCORDANCE; ASSAYS;
D O I
10.3390/cancers15051511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary PD-L1 analysis in TNBC is essential for selecting patients eligible for immunotherapy. Limited data are available on pathologists' concordance regarding PD-L1 assessment. Twelve pathologists of various expertise from three European countries digitally analysed 100 breast cancer core biopsies stained using the SP142 PD-L1 assay in two rounds. The overall inter-observer agreement among the pathologists was substantial. The intra-observer agreement was substantial to almost perfect. The expert scorers were more concordant in evaluating staining percentage compared with those of the non-experts. Challenging cases around the 1% cut-off value for positivity were identified and represented a small 6-8%) proportion of all cases. The experts were more concordant in scoring those cases. The study shows reassuringly strong inter- and intra-observer concordance among pathologists in PD-L1 scoring. A proportion of low-expressors remain challenging to assess, and these would benefit from addressing the technical issues, testing a different sample and/or referring for expert opinions. The assessment of PD-L1 expression in TNBC is a prerequisite for selecting patients for immunotherapy. The accurate assessment of PD-L1 is pivotal, but the data suggest poor reproducibility. A total of 100 core biopsies were stained using the VENTANA Roche SP142 assay, scanned and scored by 12 pathologists. Absolute agreement, consensus scoring, Cohen's Kappa and intraclass correlation coefficient (ICC) were assessed. A second scoring round after a washout period to assess intra-observer agreement was carried out. Absolute agreement occurred in 52% and 60% of cases in the first and second round, respectively. Overall agreement was substantial (Kappa 0.654-0.655) and higher for expert pathologists, particularly on scoring TNBC (6.00 vs. 0.568 in the second round). The intra-observer agreement was substantial to almost perfect (Kappa: 0.667-0.956), regardless of PD-L1 scoring experience. The expert scorers were more concordant in evaluating staining percentage compared with the non-experienced scorers (R-2 = 0.920 vs. 0.890). Discordance predominantly occurred in low-expressing cases around the 1% value. Some technical reasons contributed to the discordance. The study shows reassuringly strong inter- and intra-observer concordance among pathologists in PD-L1 scoring. A proportion of low-expressors remain challenging to assess, and these would benefit from addressing the technical issues, testing a different sample and/or referring for expert opinions.
引用
收藏
页数:17
相关论文
共 43 条
  • [21] PD-L1 Immunohistochemical Comparability Multi-Institutional Study in Esophageal Squamous Cell Carcinoma
    Liu, Yueping
    Wang, Xinran
    He, Jiankun
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 486 - 487
  • [22] PD-L1 Immunohistochemical Comparability Multi-Institutional Study in Esophageal Squamous Cell Carcinoma
    Liu, Yueping
    Wang, Xinran
    He, Jiankun
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 486 - 487
  • [23] PD-L1 Immunohistochemical Comparability Multi-Institutional Study in Esophageal Squamous Cell Carcinoma
    Liu, Yueping
    Wang, Xinran
    He, Jiankun
    MODERN PATHOLOGY, 2022, 35 : 486 - 487
  • [24] PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma A Multi-institutional Study
    Agarwal, Shipra
    Jung, Chan Kwon
    Gaddam, Pranitha
    Hirokawa, Mitsuyoshi
    Higashiyama, Takuya
    Hang, Jen-Fan
    Lai, Wei-An
    Keelawat, Somboon
    Liu, Zhiyan
    Na, Hee Young
    Park, So Yeon
    Fukuoka, Junya
    Satoh, Shinya
    Mussazhanova, Zhanna
    Nakashima, Masahiro
    Kakudo, Kennichi
    Bychkov, Andrey
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024, 48 (10) : 1233 - 1244
  • [25] Comparison of SDSG and CARDS classifications for L5/S1 lumbar degenerative spondylolisthesis: an independent inter- and intra-observer agreement study
    Zhengwang Sun
    Chongqing Xu
    Mengchen Yin
    Wangjun Yan
    Journal of Orthopaedic Surgery and Research, 16
  • [26] Comparison of SDSG and CARDS classifications for L5/S1 lumbar degenerative spondylolisthesis: an independent inter- and intra-observer agreement study
    Sun, Zhengwang
    Xu, Chongqing
    Yin, Mengchen
    Yan, Wangjun
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2021, 16 (01)
  • [27] Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
    Hoda, Raza Syed
    Brogi, Edi
    Dos Anjos, Carlos Henrique
    Grabenstetter, Anne
    Ventura, Katia
    Patil, Sujata
    Selenica, Pier
    Weigelt, Britta
    Reis-Filho, Jorge Sergio
    Traina, Tiffany
    Robson, Mark
    Norton, Larry
    Wen, Hannah Yong
    MODERN PATHOLOGY, 2020, 33 (11) : 2221 - 2232
  • [28] How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
    Wang, Xinran
    Wang, Liang
    Bu, Hong
    Zhang, Ningning
    Yue, Meng
    Jia, Zhanli
    Cai, Lijing
    He, Jiankun
    Wang, Yanan
    Xu, Xin
    Li, Shengshui
    Xiao, Kaiwen
    Yan, Kezhou
    Tian, Kuan
    Han, Xiao
    Huang, Junzhou
    Yao, Jianhua
    Liu, Yueping
    NPJ BREAST CANCER, 2021, 7 (01)
  • [29] How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
    Xinran Wang
    Liang Wang
    Hong Bu
    Ningning Zhang
    Meng Yue
    Zhanli Jia
    Lijing Cai
    Jiankun He
    Yanan Wang
    Xin Xu
    Shengshui Li
    Kaiwen Xiao
    Kezhou Yan
    Kuan Tian
    Xiao Han
    Junzhou Huang
    Jianhua Yao
    Yueping Liu
    npj Breast Cancer, 7
  • [30] PD-L1 Expression in Cytological NSCLC Cell-Blocks: a Comparative Study of the Inter and Intra-Observer Variability between Conventional and Algorithm-Based Assessments
    Garcia-Porrero, Guillermo
    Argueta, Allan
    Villalba Esparza, Maria
    Soldevilla, Ramon
    Luisa Bayo, Maria
    Echeveste, Jose
    Alvarez Gigli, Laura
    Abengozar Muela, Marta
    Garcia Tobar, Laura
    de Andrea, Carlos
    Lozano, Maria
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 258 - 258